title: Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase.
abstract: Leukemia inhibitory factor (LIF) signals via the heterodimeric receptor complex comprising the LIF receptor alpha subunit (LIFRalpha) and the common signal transducing subunit for interleukin-6 cytokine receptors, gp130. This study demonstrates that in different cell types, the level of LIFRalpha decreases during treatment with LIF or the closely related cytokine oncostatin M (OSM). Moreover, insulin and epidermal growth factor induce a similar LIFRalpha down-regulation. The regulated loss of LIFRalpha is specific since neither gp130 nor OSM receptor beta shows a comparable change in turnover. LIFRalpha down-regulation correlates with reduced cell responsiveness to LIF. Using protein kinase inhibitors and point mutations in LIFRalpha, we demonstrate that LIFRalpha down-regulation depends on activation of extracellular signal-regulated kinase 1/2 and phosphorylation of the cytoplasmic domain of LIFRalpha at serine 185. This modification appears to promote the endosomal/lysosomal pathway of the LIFRalpha. These results suggest that extracellular signal-regulated kinase-activating factors like OSM and growth factors have the potential to lower specifically LIF responsiveness in vivo by regulating LIFRalpha half-life.
authors.affiliation: Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, INSERM U463, France. frederic.blanchard@roswellpark.org
authors.forename: F
authors.initials: F
authors.lastname: Blanchard
authors.forename: L
authors.initials: L
authors.lastname: Duplomb
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: O
authors.initials: O
authors.lastname: Robledo
authors.forename: E
authors.initials: E
authors.lastname: Kinzie
authors.forename: V
authors.initials: V
authors.lastname: Pitard
authors.forename: A
authors.initials: A
authors.lastname: Godard
authors.forename: Y
authors.initials: Y
authors.lastname: Jacques
authors.forename: H
authors.initials: H
authors.lastname: Baumann
mesh_terms: D016475:3T3 Cells; D020816:Amino Acid Motifs; D000818:Animals; D015536:Down-Regulation; D004705:Endocytosis; D004789:Enzyme Activation; D006131:Growth Inhibitors / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008113:Liver Neoplasms / Q000378:metabolism; D008222:Lymphokines / Q000494:pharmacology; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D019950:Mitogen-Activated Protein Kinase 1 / Q000502:physiology*; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology*; D051381:Rats; D018121:Receptors, Cytokine / Q000378:metabolism*; D053606:Receptors, OSM-LIF
chemical_list: D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; C507840:LIFR protein, human; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; C507838:Lif protein, mouse; C507841:Lifr protein, mouse; C507842:Lifr protein, rat; D008222:Lymphokines; D018121:Receptors, Cytokine; D053606:Receptors, OSM-LIF; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases